CN112638378A - 用于根除幽门螺杆菌的组合物 - Google Patents

用于根除幽门螺杆菌的组合物 Download PDF

Info

Publication number
CN112638378A
CN112638378A CN201980055865.9A CN201980055865A CN112638378A CN 112638378 A CN112638378 A CN 112638378A CN 201980055865 A CN201980055865 A CN 201980055865A CN 112638378 A CN112638378 A CN 112638378A
Authority
CN
China
Prior art keywords
acceptable salt
pharmaceutically acceptable
clarithromycin
amoxicillin
helicobacter pylori
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980055865.9A
Other languages
English (en)
Chinese (zh)
Inventor
金奉泰
金东圭
金银枝
李志元
吴京珉
金安荣
宋根石
柳信永
金恩镜
申娜利
姜泫旨
金载玟
朴柔静
郑荷娜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inoon Ltd
Original Assignee
Inoon Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inoon Ltd filed Critical Inoon Ltd
Publication of CN112638378A publication Critical patent/CN112638378A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201980055865.9A 2018-08-29 2019-08-28 用于根除幽门螺杆菌的组合物 Pending CN112638378A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2018-0102250 2018-08-29
KR20180102250 2018-08-29
PCT/KR2019/011017 WO2020045992A1 (en) 2018-08-29 2019-08-28 Composition for eradicating helicobacter pylori

Publications (1)

Publication Number Publication Date
CN112638378A true CN112638378A (zh) 2021-04-09

Family

ID=69643254

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980055865.9A Pending CN112638378A (zh) 2018-08-29 2019-08-28 用于根除幽门螺杆菌的组合物

Country Status (25)

Country Link
US (2) US20210196685A1 (https=)
EP (1) EP3843723B1 (https=)
JP (1) JP7189327B2 (https=)
KR (1) KR20200026118A (https=)
CN (1) CN112638378A (https=)
AR (1) AR116026A1 (https=)
AU (1) AU2019328903B2 (https=)
CA (1) CA3107624C (https=)
DK (1) DK3843723T3 (https=)
EA (1) EA202190622A1 (https=)
ES (1) ES3060114T3 (https=)
FI (1) FI3843723T3 (https=)
GE (2) GEP20227431B (https=)
JO (1) JOP20190201B1 (https=)
LT (1) LT3843723T (https=)
MX (1) MX2021002278A (https=)
MY (1) MY195494A (https=)
PH (1) PH12021550385A1 (https=)
PT (1) PT3843723T (https=)
RS (1) RS67791B1 (https=)
SG (1) SG11202101920WA (https=)
SI (1) SI3843723T1 (https=)
UA (1) UA126993C2 (https=)
UY (1) UY38348A (https=)
WO (1) WO2020045992A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CA3132575A1 (en) * 2019-04-18 2020-10-22 Thomas Julius Borody Compositions and methods for treating, ameliorating and preventing h. pylori infections
WO2024210689A1 (ko) * 2023-04-07 2024-10-10 제이더블유중외제약 주식회사 벤즈이미다졸 유도체의 염
TW202535382A (zh) * 2023-11-29 2025-09-16 南韓商第一藥品股份有限公司 包含ｚａｓｔａｐｒａｚａｎ或其醫藥上可接受的鹽之用於幽門螺旋桿菌根除的組成物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101015694A (zh) * 2006-02-07 2007-08-15 沈阳东宇药业有限公司 一种治疗幽门螺旋杆菌感染的复方口服制剂
CN101341149A (zh) * 2005-12-19 2009-01-07 辉瑞大药厂 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途
WO2018056697A1 (ko) * 2016-09-21 2018-03-29 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염
CN108012527A (zh) * 2015-06-08 2018-05-08 Cj医药健康株式会社 苯并咪唑衍生物用于夜间酸突破的用途
US20200268769A1 (en) * 2016-01-21 2020-08-27 Dexcel Pharma Technologies Ltd. Methods for treating helicobacter infection

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753324B2 (en) * 1998-07-15 2004-06-22 Hassan Jomaa Phosphorous organic compounds and their use
CN108379258B (zh) * 2017-11-30 2020-02-18 中国医学科学院医药生物技术研究所 瑞香素在抗幽门螺杆菌中的应用

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101341149A (zh) * 2005-12-19 2009-01-07 辉瑞大药厂 经色原烷取代的苯并咪唑类和它们作为酸泵抑制剂的用途
CN101015694A (zh) * 2006-02-07 2007-08-15 沈阳东宇药业有限公司 一种治疗幽门螺旋杆菌感染的复方口服制剂
CN108012527A (zh) * 2015-06-08 2018-05-08 Cj医药健康株式会社 苯并咪唑衍生物用于夜间酸突破的用途
US20200268769A1 (en) * 2016-01-21 2020-08-27 Dexcel Pharma Technologies Ltd. Methods for treating helicobacter infection
WO2018056697A1 (ko) * 2016-09-21 2018-03-29 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NISHIZAWA T, ET AL.: ""Effects of patient age and choice of antisecretory agent on success of eradication therapy for Helicobacter pylori infection"" *

Also Published As

Publication number Publication date
EP3843723A1 (en) 2021-07-07
UY38348A (es) 2020-03-31
KR20200026118A (ko) 2020-03-10
SG11202101920WA (en) 2021-04-29
MX2021002278A (es) 2021-08-11
WO2020045992A1 (en) 2020-03-05
CA3107624C (en) 2023-10-03
BR112021003578A2 (pt) 2021-05-18
AU2019328903A1 (en) 2021-04-29
ES3060114T3 (https=) 2026-03-25
DK3843723T3 (da) 2026-02-09
GEP20227431B (en) 2022-10-25
LT3843723T (lt) 2026-03-25
EP3843723A4 (en) 2022-06-29
AU2019328903A8 (en) 2021-05-27
UA126993C2 (uk) 2023-03-01
PH12021550385A1 (en) 2021-09-20
CA3107624A1 (en) 2020-03-05
MY195494A (en) 2023-01-26
JOP20190201A1 (ar) 2020-02-29
US20250241897A1 (en) 2025-07-31
JP2021535910A (ja) 2021-12-23
AR116026A1 (es) 2021-03-25
US20210196685A1 (en) 2021-07-01
PT3843723T (pt) 2026-01-27
EP3843723B1 (en) 2026-01-07
FI3843723T3 (fi) 2026-02-12
JP7189327B2 (ja) 2022-12-13
JOP20190201B1 (ar) 2024-04-18
GEAP202215593A (en) 2022-07-11
EA202190622A1 (ru) 2021-06-10
SI3843723T1 (sl) 2026-04-30
AU2019328903B2 (en) 2023-01-05
RS67791B1 (sr) 2026-03-31

Similar Documents

Publication Publication Date Title
US20250241897A1 (en) Composition for eradicating helicobacter pylori
TW202600133A (zh) 治療胃腸道基質瘤方法
KR20150038736A (ko) 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
US11938123B2 (en) Use of 2,3,5-substituted thiophene compound to prevent, ameliorate, or treat breast cancers
JP2008540570A (ja) 遅発性化学療法誘発悪心及び嘔吐のドロナビノール治療
TWI746610B (zh) 9-胺甲基米諾四環素化合物及其用途
JP2004525940A (ja) 火照りの処置のためのデュロキセチン
JP2023126955A (ja) ベンズイミダゾール誘導体化合物を含む医薬組成物
CN117159553A (zh) 慢性手部湿疹的治疗
WO2022253034A1 (zh) 吡咯并嘧啶类化合物的用途
CN1204881C (zh) 烯丙胺衍生物在制备治疗幽门螺杆菌感染和相关疾病的药物方面的用途
EP4628081A1 (en) Composition for removing helicobacter pylori comprising zastaprazan or pharmaceutically acceptable salt thereof
EA043853B1 (ru) Композиция для эрадикации helicobacter pylori
JP6042886B2 (ja) 早漏症治療用の薬学組成物
US9649289B1 (en) Method and composition for treating dysbiosis and related disease states
JP3937448B2 (ja) Ｈ．ｐｙｌｏｒｉに起因する胃腸障害の処置のためのスピラマイシンの使用
BR112021003578B1 (pt) Composição e método para erradicar helicobacter pylori
KR20230027226A (ko) 화학요법-유발 설사를 치료하기 위한 방법 및 조성물
JP2025538641A (ja) ザスタプラザンまたはこの薬剤学的に許容される塩を含むヘリコバクター・ピロリ除菌用組成物
JP2025528218A (ja) ピロリ菌（Ｈ．ｐｙｌｏｒｉ）感染症を予防または処置する方法
TWI735658B (zh) 用於減少代謝症候群之組合物及其應用
WO2025103428A1 (zh) 中重度斑块型银屑病的治疗
HK40121190A (zh) 脉管畸形用药物组合物及脉管畸形的治疗方法
CN120661505A (zh) 一种治疗幽门螺杆菌的复方制剂及其制备方法
CN114558009A (zh) 一种由阿莫西林和西咪替丁制备的复方制剂及制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination